Cas:1249848-14-3 N-ethylpiperidin-3-amine manufacturer & supplier

Chemical Name:N-ethylpiperidin-3-amine

CAS.NO:1249848-14-3

Synonyms:ethylpiperidin-3-yl-amine;HT1015

Molecular Formula:C₇H₁₆N₂

Molecular Weight:128.21500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:24.06000

Exact Mass:128.13100

LogP:1.06760

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethylpiperidin-3-yl-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,HT1015 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,HT1015 Use and application,ethylpiperidin-3-yl-amine technical grade,usp/ep/jp grade.

Related News: ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. N-ethylpiperidin-3-amine manufacturer INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. N-ethylpiperidin-3-amine supplier Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. N-ethylpiperidin-3-amine vendor Travel alerts: As the Wuhan coronavirus spreads around China, infecting more people, a number of countries have raised their travel advisory warnings. N-ethylpiperidin-3-amine factory ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety.